Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon May 18, 2024 10:01pm
108 Views
Post# 36047659

RE:RE:RE:Type C Meeting Timings

RE:RE:RE:Type C Meeting Timingsat about the 24:20 mark, matt said we have submitted a type c request for a meeting, and we will have that later in the month and then the fda will have 35 days to (and i could not understand what matt said at that point).

replayed it a number of time but i just could not make out what he said.

no mention was made that i heard regarding oncy's submission of a meeting package which is due at least 47 days before the scheduled date of the meeting

once the meeting is held, the gov't has 30 calendar days to submit minutes of the meeting.

still uncertain from listening to that and then comparing that to the fda guideline that the meeting will occur next week.

however, we could hear from matt's comments about the pancan disappointment that oncy was almost immediately working with gcar to refloat the precision promise deal oncy had with pancan.

so who really knows what is going on with the fda and what to make of their timeline.

guess time will tell.
<< Previous
Bullboard Posts
Next >>